Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
← catalyst calendarNCT07521475 · readout in 127 d
Sponsored by Insulet Corporation (industry) · PODD — their whole pipeline →. With Jaeb Center for Health Research.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
350estimated
Sites
27
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-30 | actual | When the study began enrolling |
| Primary completion | 2026-12-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-23 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes Mellitus
Interventions
- Device: Device: Omnipod M System with study CGM — also filed as Omnipod M System
- Device: Standard Therapy plus study CGM — also filed as Control group
Primary outcome
what the primary-completion date above is the date OFHbA1c
measured 15 and 26 weeks
Permalink · PODD's whole pipeline · Catalyst calendar · Every registered study · What changed